Clinical trial · Observational

VIA Versus Colposcopy

Visual Inspection With Acetic Acid of The Cervix Versus Colposcopy in Screening and Detection of Cervical Intraepithelial Neoplasia

NCT07692919CI-TRIAL-00117396not yet recruitingClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The aim of this study is to compare the effectiveness of visual inspection with acetic acid (VIA) versus colposcopy in terms of sensitivity and specificity in diagnosis of pre-malignant cervical lesions among women, and to assess the awareness of women regarding cervical cancer screening methods.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Cervical Intraepithelial Neoplasia (CIN)	Cervical Intraepithelial Neoplasia	ALIAS	0.90
Cervicitis	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
VIA	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (2)

measure
VIA Versus Colposcopy in terms of in terms of sensitivity and specificity
timeFrame
2 weeks
description
Patients will be observed for any immediate discomfort or minor complications such as spotting, mild cramping, or vaginal irritation following VIA, colposcopy, or biopsy. All patients will be advised on post-procedure care, including avoiding vaginal do
measure
sensitivity and specificity in diagnosis of pre-malignant cervical lesions among women
timeFrame
From enrollment to the the result at 14 days
description
Patients will be observed for any immediate discomfort or minor complications such as spotting, mild cramping, or vaginal irritation following VIA, colposcopy, or biopsy. All patients will be advised on post-procedure care, including avoiding vaginal douching, sexual activity, or use of tampons for a few days, if a biopsy will be performed. Results of the VIA, colposcopy, and histopathology will be explained to the patients, and appropriate follow-up or referral will be arranged for those with CIN 2, CIN 3, or carcinoma. Patients will be instructed to report any unusual bleeding, pain, or discharge immediately to the clinic.

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 25 Years
Maximum age: 65 Years

Show eligibility criteria text

Inclusion Criteria:

* Age from 25 to 65 years.
* Patient undergoing cervical cancer screening using VIA and colposcopy.
* Women with symptoms such as white discharge, post-coital bleeding, and intermenstrual bleeding.
* Women with the clinically unhealthy cervix (erosion, bleeding on touch, simple leukoplakia, keratinization)
* Women with Pap smear showing dysplasia.

Exclusion Criteria:

* • Pregnant women (if VIA or colposcopy is contraindicated).

  * Women with obvious invasive cervical cancer diagnosed previously.
  * Women who refuse to provide informed consent or are unable to cooperate with the examination.
  * Women having active vaginal bleeding.
  * Any past treatment for cervical lesions.

References

Publications (0)

Data not yet available

No reference posted for this study.